BioLargo (BLGO) director granted 101,736-share stock option for board fees

Rhea-AI Filing Summary

BioLargo, Inc. reported that one of its directors received a new stock option grant as part of board compensation. On 12/31/2025, the director was granted an option to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share. The option becomes exercisable on 12/31/2025 and expires on 12/31/2035, giving the director a 10-year window to exercise once vested. After this grant, the director beneficially owned 1,265,761 derivative securities tied to the company’s stock. The filing explains that the option was issued in lieu of $18,750 in fees owed for serving on the board for the most recently completed quarter, under BioLargo’s 2024 Equity Incentive Plan, highlighting the company’s use of equity-based compensation for its directors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bray Christina Elaine

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CA 92683

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.1843	12/31/2025		A		101,736		12/31/2025	12/31/2035	Common Stock	101,736	(1)	1,265,761	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

	/s/ John R. Browning, attorney-in-fact	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLargo (BLGO) disclose in this Form 4?

BioLargo disclosed that a director received a stock option on 12/31/2025, giving the right to purchase 101,736 shares of common stock at an exercise price of $0.1843 per share.

Why did the BioLargo (BLGO) director receive the option for 101,736 shares?

The option was issued as payment for $18,750 in fees owed to the director for services on the board of directors for the most recently completed quarterly period, under the company’s 2024 Equity Incentive Plan.

When can the BioLargo (BLGO) director exercise the new stock option and when does it expire?

The stock option becomes exercisable on 12/31/2025 and has an expiration date of 12/31/2035, providing a 10-year exercise period after it becomes exercisable.

What is the exercise price of the BioLargo (BLGO) director’s new option grant?

The director’s option has an exercise price of $0.1843 per share for 101,736 underlying shares of BioLargo common stock.

How many derivative securities does the BioLargo (BLGO) director hold after this transaction?

After this option grant, the director beneficially owned 1,265,761 derivative securities related to BioLargo common stock, held in direct ownership form.

Is the BioLargo (BLGO) reporting person a director, officer, or major shareholder?

The reporting person is identified as a Director of BioLargo. The Form 4 indicates the “Director” box is checked, and the filing is made by one reporting person.